TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01730118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Description: autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Description: autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Description: autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Description: autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Description: autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
Study: NCT03051529

Intervention type: OTHER
Intervention: combined spinal epidural anesthesia
Description: After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
Study: NCT01868516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmecamylamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmecamylamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmecamylamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01857362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 20 mg
Description: Nitisinone 20 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitisinone 10 mg
Description: Nitisinone 10 mg capsules
Study: NCT04759118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified childbirth education program
Description: The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
Study: NCT04163185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-07 (MoSEIC meloxicam and rizatriptan)
Description: AXS-07 tablet taken once upon the earliest onset of migraine pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken once upon the earliest onset of migraine pain.
Study: NCT01905371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Therapy
Description: One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03323983

Intervention type: OTHER
Intervention: data collection
Description: data collection

Intervention type: OTHER
Intervention: data collection
Description: data collection
Study: NCT02243436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Intravenose use, 40mg/m2/day, on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soludomerin
Description: Intravenous use, 250mg/day, on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous use, 25mg/m2/day, on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara C
Description: Intravenous use, 2g/m2, day 5
Study: NCT03729999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable, Point-of-Care Ultrasound
Description: Portable ultrasonography done at the bedside.
Study: NCT03715738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm 1 : Creaform3D + MyotonPRO
Description: After inclusion,are carried out:~* estimation of the volume of the breast to be reduced with the 3D digital camera~* measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete.
Study: NCT01083407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine Digluconate
Description: Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothbrushing
Description: Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
Study: NCT04526704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: 200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: 200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
Study: NCT03765918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 100 mg/m^2
Description: 100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m^2
Description: 100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
Study: NCT03468218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01276509

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00547659 SC injection
Description: Placebo delivered SC, 3 doses separated by 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC injection
Description: Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
Study: NCT02546661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736
Study: NCT01276509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC injection
Description: Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
Study: NCT02546661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736
Study: NCT04010760

Intervention type: DIAGNOSTIC_TEST
Intervention: Test of biomarkers for PE in EBC
Description: New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2\*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient.
Study: NCT01276509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC injection
Description: Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
Study: NCT03390270

Intervention type: OTHER
Intervention: Admission with NSTEMI
Description: All patients admitted to Duke University Hospital with an NSTEMI
Study: NCT03685253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
Study: NCT02546661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: MEDI4736 (durvalumab) + Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: MEDI4736 (durvalumab) + AZD1775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: MEDI4736 (durvalumab) + Vistusertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: MEDI4736 (durvalumab) + AZD9150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: MEDI4736 (durvalumab) + Selumetinib
Study: NCT03524183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Fitness Buddy Ecosystem
Description: The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Fitness Buddy Ecosystem
Description: The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
Study: NCT04420221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag half dose non-adjuvanted
Description: 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag full dose non-adjuvanted
Description: 1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag half dose adjuvanted
Description: 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag full dose adjuvanted
Description: A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag full dose adjuvanted
Description: A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.
Study: NCT02923180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
Study: NCT04293055

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance program
Description: 1-year weight loss maintenance program, consisting of monthly newsletters
Study: NCT01904253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amrubicin (Japan)
Description: Patients will receive treatment administered according to the country-specific approved prescribing information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan (Japan/Europe)
Description: Patients will receive treatment administered according to the country-specific approved prescribing information
Study: NCT03603223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00489489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Teriflunomide)
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-β
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Study: NCT04293055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance program
Description: 1-year weight loss maintenance program, consisting of monthly newsletters

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone coaching
Description: Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
Study: NCT03641313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography Assisted Biopsy
Description: Undergo CT assisted biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Biopsy
Description: Undergo endoscopic biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI